© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
March 11, 2016
Bible says most oncologists would consider lenvatinib as a first-line therapy for patients who require systemic therapy where there are not suitable, focal palliative options.
January 28, 2015
Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the challenges associated with treating patients with follicular cell-derived thyroid carcinoma.